Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study [Corrigendum]
Bloom CI, Douglas I, Usmani OS, Quint JK. Int J Chron Obstruct Pulmon Dis. 2020;15:701–710.
The authors have advised that there should be an added Funding section. The funding statement is as follows:
This study was funded by an Investigator Initiated Study from Chiesi. Chiesi had no role in the design, analysis, interpretation of findings or writing of the manuscript.
On page 709 the disclosure section should be presented as follows:
OSU and JKQ are co-last authors to this study. JKQ reports funding outside the submitted work from AstraZeneca, Asthma UK, The Health Foundation, MRC, Wellcome Trust, BLF, GlaxoSmithKline, Insmed, Bayer, IQVIA, and Boehringer Ingelheim and funding from AstraZeneca, GlaxoSmithKline, Chiesi, Bayer, Teva, and Boehringer Ingelheim for Advisory board participation or travel. ID reports grants outside the submitted work from NIHR, GlaxoSmithKline, MRC, ABPI. OSU reports from outside the submitted work grants from AstraZeneca, Edmond Pharma and GlaxoSmithKline; personal fees from Aerocrine, Boehringer Ingelheim, Cipla, Mundipharma, Napp, Sandoz, Takeda and Zentiva. The authors report no other conflicts of interest in this work.
The authors apologize for these errors.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]